TuHURA Biosciences Advances Clinical Trials and Strengthens Market Position

TuHURA Biosciences ( (HURA) ) has issued an announcement.

TuHURA Biosciences has announced significant advancements in its clinical trials and corporate strategy. The company completed the acquisition of Kineta, Inc., enhancing its pipeline with a novel VISTA inhibiting antibody, TBS-2025, and plans to initiate a Phase 2 trial for relapsed/refractory NPM1-mutated AML. Additionally, TuHURA has initiated a Phase 3 accelerated approval trial of IFx-2.0 in combination with Keytruda for MCC, which could lead to time and cost savings if successful. The company also strengthened its financial position with a $12.5 million equity financing and $3 million from warrant exercises, and it was included in the Russell 3000 and 2000 Indexes, reflecting its growing market presence.

The most recent analyst rating on (HURA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.

Spark’s Take on HURA Stock

According to Spark, TipRanks’ AI Analyst, HURA is a Underperform.

TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company’s poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.

To see Spark’s full report on HURA stock, click here.

More about TuHURA Biosciences

TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company focused on developing novel technologies to overcome resistance to cancer immunotherapy. The company is engaged in the development of treatments for advanced and metastatic cancers, with a particular focus on leveraging antibody peptide or drug candidate technologies.

Average Trading Volume: 439,930

Technical Sentiment Signal: Sell

Current Market Cap: $151.3M

For an in-depth examination of HURA stock, go to TipRanks’ Overview page.